BIO FY 2021 Earnings Report — Bio-Rad Laboratories, Inc. Revenue & Financial Results | Market Cap Arena

Bio-Rad Laboratories, Inc.BIO

FY 2021 Earnings

Reported February 11, 2022

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2021	Prior Q	FY 2020	QoQ Change	YoY Change
Revenue	$2.9B	—	$2.5B	—	14.8%
Op. Income	$500M	—	$421M	—	18.8%
Gross Margin	56.1%	—	56.5%	—	-0.4pp
Net Margin	145.6%	—	149.8%	—	-4.3pp
EPS (Diluted)	$140.83	—	$126.20	—	11.6%
Free Cash Flow	$536M	—	$476M	—	12.4%

Revenue Flow

Item	Amount
REVENUE	$2.9B
Cost of Revenue	$1.3B
GROSS PROFIT	$1.6B
R&D Expenses	$261M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$877M
Other Expenses	$0
Operating Expenses	$1.1B
Cost & Expenses	$2.4B
OPERATING INCOME	$500M
Interest Income	$19M
Interest Expense	$2M
Other Income/Expenses	$4.9B
INCOME BEFORE TAX	$5.4B
Income Tax Expense	$1.2B
Net Income from Continuing Ops	$4.3B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.3B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.3B
D&A	$138M
EBIT	$5.5B
EBITDA	$5.6B
EPS	$143
EPS Diluted	$141

Income Statement

Item	Amount
REVENUE	$2.9B
Cost of Revenue	$1.3B
GROSS PROFIT	$1.6B
R&D Expenses	$261M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$877M
Other Expenses	$0
Operating Expenses	$1.1B
Cost & Expenses	$2.4B
OPERATING INCOME	$500M
Interest Income	$19M
Interest Expense	$2M
Other Income/Expenses	$4.9B
INCOME BEFORE TAX	$5.4B
Income Tax Expense	$1.2B
Net Income from Continuing Ops	$4.3B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.3B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.3B
D&A	$138M
EBIT	$5.5B
EBITDA	$5.6B
EPS	$143
EPS Diluted	$141

Cash Flow Statement

Item	Amount
Net Income	$4.3B
Depreciation & Amortization	$138M
Stock-Based Compensation	$51M
Deferred Income Tax	$0
Other Non-Cash Items	-$4.9B
Change in Working Capital	$1.1B
OPERATING CASH FLOW	$669M
Capital Expenditure	-$134M
Acquisitions (Net)	-$126M
Purchases of Investments	-$852M
Sales/Maturities of Investments	$767M
Other Investing Activities	-$453M
NET CASH FROM INVESTING	-$797M
Net Debt Issuance	-$3M
Common Stock Repurchased	-$50M
Common Dividends Paid	$0
Other Financing Activities	-$2M
NET CASH FROM FINANCING	-$55M
FREE CASH FLOW	$536M
Net Change in Cash	-$196M

Balance Sheet

Item	Amount
Cash & Equivalents	$471M
Short-Term Investments	$399M
Net Receivables	$424M
Inventory	$572M
Other Current Assets	$16M
TOTAL CURRENT ASSETS	$2.0B
PP&E (Net)	$716M
Goodwill	$347M
Intangible Assets	$254M
Long-Term Investments	$14.4B
Tax Assets	$0
Other Non-Current Assets	$104M
TOTAL NON-CURRENT ASSETS	$15.8B
TOTAL ASSETS	$17.8B
Account Payables	$142M
Short-Term Debt	$489.0K
Deferred Revenue	$51M
Other Current Liabilities	$128M
TOTAL CURRENT LIABILITIES	$681M
Long-Term Debt	$11M
Deferred Revenue NC	$0
Deferred Tax Liabilities	$3.1B
Other Non-Current Liabilities	$182M
TOTAL NON-CURRENT LIABILITIES	$3.4B
TOTAL LIABILITIES	$4.1B
Common Stock	$3.0K
Additional Paid-In Capital	$442M
Retained Earnings	$13.5B
Treasury Stock	-$106M
Accum. Other Comp. Income	-$176M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$13.7B
Minority Interest	$0
TOTAL EQUITY	$13.7B
TOTAL LIABILITIES & EQUITY	$17.8B
Total Debt	$223M
Net Debt	-$247M